

1 **Development of an intervention to support the implementation of evidence-based strategies**
2 **for optimising antibiotic prescribing in general practice**

3 **Authors**

4 Aleksandra J. Borek,^{1*} Anne Campbell,² Elle Dent¹, Michael Moore,³ Christopher C. Butler,¹ Alison
5 Holmes,² A. Sarah Walker,^{4,5,6} Monsey Mcleod,^{2,7,8**} Sarah Tonkin-Crine,^{1,4**} on behalf of the STEP-UP
6 study team[†]

7 **Affiliations**

- 8 1. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
- 9 2. National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare
10 Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK
- 11 3. Primary Care Population Sciences and Medical Education, Faculty of Medicine, University of
12 Southampton, UK
- 13 4. NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial
14 Resistance, University of Oxford, Oxford, UK
- 15 5. NIHR Oxford Biomedical Research Centre, Oxford, UK
- 16 6. Nuffield Department of Medicine, University of Oxford, Oxford, UK
- 17 7. Centre for Medication Safety and Service Quality, Pharmacy Department, Imperial College
18 Healthcare NHS Trust, London, UK
- 19 8. NIHR Imperial Patient Safety Translational Research Centre, Imperial College London, London,
20 UK

21 * Corresponding author: Aleksandra Borek, Nuffield Department of Primary Care Health Sciences,
22 University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK.
23 Email: Aleksandra.borek@phc.ox.ac.uk; Tel.: +44(0) 1865 289 337.

24 **Joint last authors

25 † Members of the STEP-UP study team are listed in the Acknowledgments section.

26

27 **Abstract**

28 **Background:** Trials show that antimicrobial stewardship (AMS) strategies, including communication
29 skills training, point-of-care C-reactive protein testing (POC-CRPT) and delayed prescriptions, help
30 optimise antibiotic prescribing and use in primary care. However, use of these strategies in general
31 practice is limited and inconsistent. We aimed to develop interventions to enhance uptake and
32 implementation of these strategies in primary care.

33 **Methods:** We drew on the Person-Based Approach to develop an implementation intervention in
34 two stages. (1) Planning and design: We defined the problem in behavioural terms drawing on
35 existing literature and conducting primary qualitative research (nine focus groups) in high-
36 prescribing general practices. We identified 'guiding principles' with intervention objectives and key
37 features, and developed logic models representing intended mechanisms of action. (2) Developing
38 the intervention: We created prototype intervention materials and discussed and refined these with
39 input from 13 health professionals and 14 citizens in two sets of design workshops. We further
40 refined the intervention materials following think-aloud interviews with 22 health professionals.

41 **Results:** Focus groups highlighted uncertainties about how strategies could be used. Health
42 professionals in the workshops suggested having practice champions, brief summaries of each AMS
43 strategy, evidence supporting the AMS strategies, and they and citizens gave examples of helpful
44 communication strategies/phrases. Think-aloud interviews helped clarify and shorten the text and
45 user journey of the intervention materials. The intervention comprised components to support
46 practice-level implementation: antibiotic champions, practice meetings with slides provided, and an
47 'implementation support' website section; and components to support individual-level uptake:
48 website sections on each AMS strategy (with evidence, instructions, links to electronic resources),
49 and material resources (patient leaflets, POC-CRPT equipment, clinician handouts).

50 **Conclusions:** We used a systematic, user-focused process of developing a behavioural intervention,
51 illustrating how it can be used in an implementation context. This resulted in a multicomponent
52 intervention to facilitate practice-wide implementation of evidence-based strategies which now

53 requires implementing and evaluating. Focusing on supporting the uptake and implementation of
54 evidence-based strategies to optimise antibiotic use in general practice is critical to further support
55 appropriate antibiotic use and mitigate antimicrobial resistance.

56

57 **Key words:** implementation, behaviour change, qualitative, antibiotic prescribing, antimicrobial
58 stewardship, antibiotic resistance, point-of-care C-reactive, delayed prescriptions, communication,
59 intervention development

60

61 **Contribution to the literature**

- 62 • This paper reports a systematic process to developing digital behavioural interventions, drawing
63 on the Person-Based Approach and combining theoretical modelling with qualitative research
64 with target users.
- 65 • It illustrates the use of this approach in an implementation context and the value of involving
66 target users at all stages of intervention development and planning implementation.
- 67 • It shows that professionals valued a brief, multicomponent implementation intervention with
68 online training, physical resources, champions and practice meetings.
- 69 • This study adds knowledge on how to develop implementation interventions for clinical settings
70 and how to best engage clinicians as the target users.

71 Background

72 Antimicrobial resistance (AMR) poses a severe global threat to public health and modern
73 medicine. Without effective antimicrobial medicines many common infections and routine medical
74 and dental procedures will become life-threatening. One of the main contributing factors to AMR is
75 over-use of antibiotics, especially in primary care where most antibiotics are prescribed (1). Many
76 antimicrobial stewardship (AMS) strategies have been used to optimise antibiotic prescribing and
77 reduce antibiotic use, especially for acute respiratory infections in primary care (2–4). Some have
78 been implemented nationally or regionally in England as part of the Quality Premium incentive
79 scheme, e.g., antibiotic prescribing targets; monitoring, feedback and benchmarking of antibiotic
80 prescribing rates; and audit and feedback to individual prescribers by prescribing advisors from
81 Clinical Commissioning Groups (CCGs) (1,5–8). Among many others, AMS strategies include using
82 enhanced communication skills and patient leaflets, point-of-care C-reactive protein testing (POC-
83 CRPT), and delayed/back-up antibiotic prescriptions (DPs). These strategies have been tested in
84 clinical trials and systematic reviews of trials support their effectiveness in reducing antibiotic
85 prescribing/use in primary care (2,4,9).

86 The GRACE-INTRO trial (10–12), a large international study (including England and Wales),
87 involved developing and testing two strategies to reduce antibiotic prescribing for lower respiratory
88 tract infections: (i) online training for general practitioners (GPs) in enhanced communication skills,
89 supported by interactive use of a patient booklet ('Caring for Coughs'), and (ii) using POC-CRPT. The
90 2x2 factorial trial tested each intervention alone, and both combined, against usual care.
91 Participating practices were also asked to appoint a lead GP to organise a structured meeting on
92 prescribing issues. The trial showed that both strategies were effective in reducing antibiotic
93 prescriptions, with the combined arm showing the biggest effect (10). At 12 month follow-up, the
94 online communication skills training showed a longer-lasting effect (11). Other trials in England have
95 also shown interactive use of leaflets can help support communication when not prescribing
96 antibiotics for children ('When Should I Worry' booklet (13)) and adults with respiratory infections

97 (Infosheets (14)). UK-based trials also have shown that giving patients DPs (instead of immediate
98 antibiotic prescriptions) with a good explanation is an effective strategy to safely reduce antibiotic
99 use by patients: showing only 33%-39% of patients use antibiotics when given a DP and that the
100 strategy helps prevent complications and reduce re-consultations and future consultations for
101 similar illnesses (15–17).

102 While trials show that these three AMS strategies are safe and effective in reducing
103 antibiotic prescriptions/use, their uptake in the ‘real world’ in English general practices is unknown
104 and, anecdotally, limited and inconsistent. The GRACE-INTRO training and booklet are currently not
105 publically available, although similar (‘STAR: Stemming the Tide of Antibiotic Resistance’)
106 communication training is (18,19). The ‘When Should I Worry’ booklet is available online (20) but it is
107 unclear how widely it is used. POC-CRPT is not routinely available in English general practices, except
108 a few local pilots (21–23). Finally, DPs are and can be used, but clinicians have varied views and
109 approaches to DPs, many report not using DPs at all, and not coding them consistently (24–26).
110 Therefore, addressing this gap between trial evidence and real-world implementation of evidence-
111 based AMS strategies is an important step following development and testing of interventions. It
112 may be particularly important for those practices that remain high prescribers of antibiotics despite
113 the availability of AMS strategies. These practices may require additional support to implement such
114 strategies (e.g. the three aforementioned evidence-based but under-utilized AMS strategies) to help
115 them optimise antibiotic prescriptions/use.

116 This study aimed to develop and evaluate an intervention to support the implementation
117 (henceforth ‘implementation intervention’ or ‘intervention’) of three evidence-based AMS strategies
118 (communication skills training with patient leaflet, POC-CRPT, and DPs) in high antibiotic prescribing
119 general practices in England. It is a part of a larger programme called STEP-UP (‘Improving the
120 uptake and SusTainability of Effective interventions to promote Prudent antibiotic Use in Primary
121 care’)(27). This paper describes the intervention development process and provides a
122 comprehensive description of the implementation intervention.

123 **Methods and Results**

124 **Overview of methods**

125 In our research we drew on elements of the Person-Based Approach (PBA) (28–30) which is
126 a systematic approach to developing behaviour change interventions, particularly those with digital
127 components. It is distinctive from other approaches in its focus on involving people from the target
128 user populations through qualitative research and co-design. The PBA helps integrate evidence and
129 theory-based intervention development (focusing on psychosocial and behavioural change processes
130 and techniques) with a user-centred design that improves the usability, acceptability and
131 engagement of technology-based interventions. It has been used to develop a wide range of health-
132 related behaviour change interventions to target patients and healthcare professionals (31),
133 including the GRACE-INTRO intervention (10,32) and a digital intervention to reduce antibiotic
134 prescriptions in hospitals (33).

135 The main elements of the PBA are: (i) undertaking qualitative research with people from the
136 target user populations at all stages of intervention development (starting with exploring
137 psychosocial and contextual influences on the target behaviour); and (ii) developing ‘guiding
138 principles’ (comprising design objectives and key intervention features to achieve objectives) and
139 theoretical integration that shows how the intervention will address the target behaviour and
140 determinants. Table 1 summarises the steps taken in our intervention development. Progress
141 through the steps was iterative so later steps fed back into earlier steps (e.g., feedback from design
142 workshops influenced the theoretical modelling). In this paper we describe the two stages of
143 planning and developing the intervention; the implementation and evaluation of the intervention
144 will be reported separately.

145 <Table 1 here>

146 Implementation intervention planning and design

147 1. Defining the problem, target behaviours, users and influences

148 *Methods*

149 In the initial part of the intervention development process, we drew on the expertise of the
150 research team, existing literature, and conducted primary qualitative research. The research team
151 were a multidisciplinary group (GPs, a pharmacist, a psychologist, sociologists, statisticians and
152 health economists and health services researchers), including researchers experienced in optimising
153 antibiotic prescribing in primary care. We used the team's expertise throughout intervention
154 development but especially in the initial planning.

155 As part of a related study (34,35), we conducted two scoping reviews of (i) studies of AMS
156 strategies (interventions) and (ii) qualitative studies on influences on antibiotic prescribing; both
157 included healthcare professionals in UK primary care and focused on prescribing for acute
158 respiratory infections. We used this evidence to identify evidence-based AMS strategies and
159 modifiable influences on antibiotic prescribing.

160 Given that much existing qualitative research with healthcare professionals about AMS
161 strategies was within trials and unspecific to implementation or high-prescribing practices, we
162 conducted our own qualitative research. The methods of this focus group study are reported in
163 detail elsewhere (26). In brief, we held nine focus groups with 50 professionals (3-11 per practice) in
164 high-prescribing practices (i.e. top 20% for antibiotic prescribing based on 2017 PrescQIPP data (6))
165 in England to better understand practice professionals' views on antibiotic prescribing, optimisation,
166 and implementing/using POC-CRPT and DPs. The focus groups were conducted by AB and AC using a
167 semi-structured topic guide and lasted 49-87 minutes. Practices were reimbursed for participation.
168 The data were analysed using an inductive thematic approach in NVivo software by four researchers
169 (AB, AC, STC, ED), and analytic saturation was achieved. The findings informed our choice of targeted
170 influences and potential intervention components.

171 *Results*

172 The problem and target behaviours: Drawing on the research team’s expertise and
173 experience, we identified the problem as low uptake and inconsistent use of evidence-based AMS
174 strategies in English general practice. Thus, the target behaviour was use of evidence-based AMS
175 strategies in a general practice consultations for acute infections. We hypothesized that increased
176 use of AMS strategies would decrease prescribing of (immediate) antibiotics. Using evidence from
177 systematic reviews and clinical trials of AMS strategies in England, expertise of the research team,
178 consideration of whether support already existed for an AMS strategy, and whether the support was
179 within scope of and feasible in our study, we selected three AMS strategies: (i) communication skills
180 training with interactive use of patient leaflets, (ii) POC-CRPT, and (iii) DPs. For communication skills
181 training and POC-CRPT, we aimed to support implementation of the training and resources
182 developed and tested in the GRACE-INTRO study (10–12,32). For DPs, existing trials did not target
183 clinician behaviour but rather aimed to assess the impact of DPs on patient behaviour (whether they
184 used antibiotics when given a DP), patient satisfaction, likelihood of re-consulting for the same or
185 different illness and the safety of delaying antibiotics (15,16); thus, we aimed to develop materials
186 targeted at clinicians to promote DP use. Other effective AMS strategies exist that were not included
187 (2–4), e.g., monitoring, feedback and benchmarking (peer comparison) of antibiotic prescribing
188 rates, and audit and feedback to individual prescribers have already been implemented in England
189 (7,8); electronic clinical decision support tools/systems (which may involve different features and
190 would require remote changes to and integration into different clinical systems software (14)) and
191 patient education were considered unfeasible within and outside of scope of our study.

192 Target users: Although antibiotic prescribing in general practices has reduced in recent
193 years, studies show that a proportion of general practices remain high-prescribing (36–38).
194 Therefore, we identified the ‘users’ or ‘population’ to target by our intervention as healthcare
195 professionals in high antibiotic prescribing practices (i.e. in the top quarter of antibiotic prescribing
196 in England). We targeted prescribers and non-prescribers in these practices because communication

197 skills (with leaflets) and POC-CRPT can be used by both prescribers and non-prescribers, whereas
198 DPs are used by prescribers. However, we also envisaged that implementation of the strategies in
199 practices may involve non-clinical practice professionals who support clinicians (e.g., receptionists
200 triaging patients for POC-CRPT or managing DPs to be collected later). Therefore, we agreed that our
201 intervention would target all general practice professionals, with a primary focus on prescribers.

202 Influences on antibiotic prescribing: We fully report the identified influences on antibiotic
203 prescribing and optimisation in our review of qualitative studies in the UK (34,35), our focus group
204 study in high-prescribing practices (26) and in Supplementary File 1. From these, we selected
205 influences considered important, modifiable by an intervention, and most feasible to address. The
206 iterative nature of the development process meant these targeted influences were further refined,
207 particularly following the workshops (step 3). Table 2 shows which influences were targeted in the
208 intervention and by which components. Supplementary File 2 reports the targeted influences
209 matched with the Theoretical Domains Framework categories (39).

210 <Table 2 here>

211 *2. Creating guiding principles and theoretical modelling*

212 *Methods*

213 After identifying target behaviours and influences, we established guiding principles for the
214 intervention. These incorporated design objectives for the intervention and its key features (i.e. how
215 it would address these objectives).

216 We developed two logic models to illustrate the intended change mechanisms. The first
217 described individual-level processes of how the AMS strategies facilitate change in clinicians'
218 antibiotic prescribing behaviour. The second described practice-level processes of how the
219 implementation intervention was intended to facilitate change in practice-wide implementation and
220 clinicians' use of the AMS strategies. The logic models were refined throughout intervention
221 development. We also identified formats by which to deliver the intervention (i.e. intervention
222 components).

223 *Results*

224 Table 3 summarises the guiding principles for the implementation intervention. We
225 identified the importance of the intervention fitting the local context; thus, rather than developing a
226 generic, prescriptive implementation plan, we aimed to support autonomy and tailoring by
227 encouraging practices to develop their own implementation plan. The intervention provided
228 professionals with a choice of AMS strategies to use, and how, by offering a range of resources,
229 including multiple patient leaflets (printed and electronic), and two types of POC-CRPT equipment
230 (qualitative and quantitative, which could be stored differently). The feedback from the design
231 workshops (step 3) and think-aloud interviews (step 4) stressed the importance of intervention
232 materials being concise and user-friendly, due to demands on professionals' time, and the
233 importance of the intervention coming from a trustworthy source.

234 <Table 3 here>

235 Our first logic model (Figure 1) illustrates how the three AMS strategies are hypothesised to
236 influence individual-level change in antibiotic prescribing behaviour. We identified the key target
237 influences on antibiotic prescribing: clinicians' perceptions of patient expectations for antibiotics
238 (influence 8 and 23, Table 2), addressed by all three AMS strategies; clinical uncertainty about
239 indication for antibiotics and illness severity and progression (influence 6), addressed by POC-CRPT
240 and DPs; concern that patients will (need to) re-consult (influence 14) and/or will be dissatisfied if
241 not receiving something tangible (e.g. prescription, leaflet) (influence 9), addressed by
242 communication strategies and DPs; and concern that the AMS strategies take too long or would
243 lengthen consultations (influence 15), addressed by the information about communication strategies
244 and DPs provided on the website as part of the intervention. Figure 1 shows these influences were
245 addressed by the three AMS strategies directly and/or by the components of the implementation
246 intervention, and then were hypothesized to facilitate change in clinicians' cognitions, leading to
247 higher uptake of the three AMS strategies and, consequently, decreased prescribing of (immediate)
248 antibiotics.

249 The second logic model (Figure 2) illustrates how the implementation intervention was
250 hypothesised to facilitate the practice-level implementation of the three AMS strategies. In
251 particular, we identified the lack of access to resources to enable use of these strategies (influence
252 21, Table 2) as a critical barrier, addressed by providing printed leaflets/booklets and POC-CRPT
253 equipment. Competing priorities, with high workloads and insufficient time (influence 14),
254 constituted also key barriers to prioritising antibiotic optimisation and implementation of new
255 strategies in practices, and were addressed by identifying practice antibiotic champions to lead AMS
256 and support colleagues in using AMS strategies. Finally, perceived inconsistency between clinicians'
257 antibiotic prescribing and use of AMS strategies (influence 19) was a barrier due to concern about
258 patients' expectations for antibiotics, dissatisfaction or re-consultations if not prescribed antibiotics;
259 this was addressed through the champion and practice meetings that aimed to ensure more
260 consistent, practice-wide approach.

261 <Figures 1 and 2 here>

262 Implementation intervention development and refinement

263 3. Developing intervention components and materials (design workshops)

264 *Methods*

265 We conducted four workshops to discuss intervention components: two in March and two in
266 June 2019, with one workshop with professionals and one with citizens (i.e. members of the public)
267 at each time-point. Workshops were in-person and lasted approximately three hours each. Informed
268 consent was taken from all participants at the start, and participants were reimbursed for
269 participation. All workshops were audio-recorded and transcribed verbatim.

270 Health professionals included GPs, nurses and CCG professionals responsible for AMS in
271 primary care. For the first workshop, we invited participants from our earlier focus-group study,
272 through professional networks, and representatives from local CCGs. These invitations were sent by
273 email. For the citizen workshop, we advertised through a website promoting opportunities for
274 public involvement in NHS, public health and social care research (www.peopleinresearch.org). All

275 attendees of the first workshops were invited to the second workshops and we sought new
276 participants as needed.

277 The first professional workshop aimed to gather views and feedback on the three AMS
278 strategies and implementation support. We facilitated discussions to allow participants to voice their
279 views and experiences around key questions. The first citizens' workshop focused on 'talking about
280 infections and antibiotics with your GP' and 'helping GPs discuss back-up/delayed prescriptions with
281 patients'. We presented citizen participants with hypothetical scenarios (e.g., consulting a GP with a
282 sore throat and a GP using certain communication strategies) to prompt discussions. Professionals
283 and citizens were given handouts with the key questions and scenarios to enable them to add
284 comments if they wished. Two researchers in each workshop made field notes.

285 After the first set of workshops, we combined field notes with data from the transcripts,
286 participants' comments from the handouts, and relevant suggestions from the focus group study. All
287 suggestions were summarised and discussed by the study team and used to develop draft
288 implementation intervention materials. For the website, we developed a website design brief and
289 worked with a professional web designer. We drafted content for the webpages and developed
290 prototypes of the webpages and resources.

291 The second professionals' workshop aimed to discuss and collect feedback on the content,
292 design and delivery of the intervention components. We presented draft webpages on the three
293 AMS strategies and resources. The second citizens' workshop further explored discussing back-
294 up/delayed prescriptions, as well as views/suggestions on helping other types of prescribers to
295 discuss prescribing decisions, and on different types of patient leaflets. Following the second set of
296 workshops, we compiled the comments and suggestions as before, and agreed changes to be made.

297 *Results*

298 The first set of workshops were attended by 11 professionals (five GPs, five CCG
299 pharmacists/prescribing advisors, one practice nurse prescriber) and by 14 citizens. The second set

325 4. Refining intervention materials (think-aloud interviews)

326 *Methods*

327 Think-aloud interviews with health professionals were used to collect detailed feedback to
328 refine the online component of the intervention and resources. Professionals were recruited from
329 those involved in previous stages of the research (e.g. workshops) and through research team
330 networks. Interviews (lasting about an hour) took place remotely or in person. All participants gave
331 informed consent and were reimbursed for their time.

332 Interviews were conducted by AB, AC, and ED between July and October 2019. Participants
333 were given a link and asked to freely navigate and read the website during the interview. They were
334 asked to read the webpages commenting ('thinking aloud') about the content, design, navigation
335 and any other aspects if they wished to. Interviews were audio-recorded and detailed notes were
336 made during the interviews.

337 Each participant's suggestions were inserted into a table, and then assessed using pre-
338 existing criteria for deciding whether to make modifications and MoSCoW ranking (i.e. Must, Should,
339 Could, Would like to change, or no change) (40). Changes that were deemed 'Must do' or simple to
340 do were addressed immediately after the interviews; other changes were addressed after every few
341 interviews. We continued the interviews until no major suggestions for changes were made and data
342 saturation was reached.

343 *Results*

344 Twenty-two professionals completed think-aloud interviews (12 GPs, 4 practice nurse
345 prescribers, 2 CCG prescribing advisors, 2 practice pharmacy prescribers, 1 pharmacy prescriber, and
346 1 advanced paramedic practitioner). The interviews lasted 37-73 (mean 56) minutes. Thirteen were
347 conducted by telephone, six face-to-face, and three by Skype.

348 Table 6 presents examples of suggestions and how we addressed them. The main changes
349 were made to the layout of webpages, improved navigation, further condensing and reducing text,
350 and providing links directly to guidelines and evidence. The most mixed views related to whom the

351 website would be useful (some found it useful, others suggested it would be useful to less
352 experienced prescribers); preferences and views on each of the three strategies; perceived lack of
353 incentive to read the website; and whether it should be formatted like an instructional course with
354 a certificate of completion. The most positive views related to content: examples of communication
355 strategies and what not to say when explaining DPs (to avoid mixed messages to patients);
356 information on typical duration of common infections; instructions on using the POC-CRPT
357 equipment and interpreting test results; suggestions for champions to address common questions
358 and concerns. Participants also liked references to guidelines and evidence, and institutional logos
359 and endorsements perceived as adding credibility. After many changes, in later interviews, they also
360 reported the text as clear, concise and 'punchy'.

361 <Table 6 here>

362 Antibiotic Optimisation implementation intervention

363 Here we describe the final version of the implementation intervention. Behaviour change
364 techniques (41) that were included in the intervention are reported in Supplementary File 2. Further
365 website details are in Supplementary File 3. The completed Template for Intervention Description
366 and Replication (TIDieR) checklist (42) is in Supplementary File 4.

367 The implementation intervention has four components (Figure 3), described below. As
368 depicted in the logic models, the intervention targeted changes at practice-level and individual-level.

369 <Figure 3 here>

370 First, practices are asked to identify a practice-based Antibiotic Champion to lead
371 implementation of the AMS strategies in the practice, and to support and encourage other clinicians.
372 The Antibiotic Champion could be a prescribing lead, GP or nurse practitioner interested in infections
373 and antibiotic optimisation, or any other clinician responsible for AMS in the practice. The role could
374 also be shared by two professionals.

375 Second, practices are asked to organise at least one practice meeting focused on antibiotic
376 optimisation and the AMS strategies. We suggest meeting(s) is/are led by the Antibiotic

377 Champion(s). The first meeting aims to raise awareness and motivation to optimise antibiotics: it
378 should focus on introducing the three AMS strategies, the Antibiotic Optimisation website and
379 associated resources, and facilitate discussions and agreement on when and how the strategies are
380 implemented in the practice. Subsequent meetings (every 2-3 months) are suggested to help remind
381 prescribers about the strategies and resources, review implementation, and inform new or locum
382 staff about them.

383 Component 3a, targeted at practice-level change, is the 'Implementation Support' section on
384 the Antibiotic Optimisation website. This introduces the champion role, suggests actions for
385 champions to promote implementation of the AMS strategies, and helps address common questions
386 and concerns. It includes guidance to help champions lead introductory and subsequent meetings
387 and four sets of PowerPoint meeting slides designed to take 5-10 minutes to go through – one set
388 providing an overview of the resources and strategies and one set each for the three strategies.

389 Component 3b, targeted at individual clinicians, are three AMS strategies (communication
390 strategies and patient leaflets, POC-CRPT, DPs) sections on the Antibiotic Optimisation website. Each
391 section includes evidence-based instructions and rationale on how and why to use the strategies,
392 examples, evidence and guidelines, and videos or quotes from clinicians describing how and why
393 they use the strategies. There are also links for electronic patient leaflets and handouts for clinicians
394 (i.e. short reminder sheets with top tips for discussing antibiotics, interpreting POC-CRPT results,
395 recording POC-CRPT results as part of training, and discussing and coding DPs).

396 The Antibiotic Optimisation website is a key component of the intervention. It is primarily
397 targeted at prescribers, but can be used by any professional involved in implementing the three AMS
398 strategies (e.g., practice nurses doing POC-CRPT). It can be used flexibly, e.g., non-sequentially as any
399 section and page can be accessed directly or sequentially by links at the bottom of each page. All
400 professionals have access to all parts of the website. Our think-aloud interviews indicated that
401 reading the whole website takes up to one hour. Supplementary File 3 reports the content of each
402 section.

403 The fourth component provides resources to enable use of the AMS strategies. These
404 include printed versions of patient leaflets/booklets and clinician handouts, and two types of POC-
405 CRPT equipment. In our focus groups time was reported to be a critical factor and participants
406 considered one of the three tests discussed to be too long for general practice consultations so we
407 excluded it from the intervention. The POC-CRPT website section directs users to providers of the
408 POC-CRPT equipment who offer in-person training. We also suggest a training task: all prescribers
409 use the POC-CRPT on the first 10 patients with acute cough and record the results on a handout.
410 The next step of this study involved implementing the implementation intervention with high-
411 prescribing general practices in England and a mixed-methods evaluation. Following this, we are in
412 the process of incorporating the resources into existing, publicly-available AMS resources. Until
413 made publicly available, the website and resources can be provided from the authors on reasonable
414 request. There is no specific number of times or period over which the intervention should be
415 delivered; rather, we envisage that health professionals engage with it in ways that suit them and
416 when they want additional support with implementing the three AMS strategies.

417 **Discussion**

418 In this paper we describe the process of developing the Antibiotic Optimisation intervention
419 to promote and support the uptake and implementation of three evidence-based AMS strategies in
420 high-prescribing general practices. This was an iterative process of intervention planning, design,
421 development and refinement, in which we combined evidence, theoretical modelling and qualitative
422 research with target users and stakeholders.

423 The Antibiotic Optimisation implementation intervention was targeted at health
424 professionals in general practice. While we focused on the context of general practice and involved
425 primary care stakeholders, the final intervention has some similarities with the Antibiotic Review Kit
426 (ARK) intervention to safely review and reduce antibiotic prescriptions in hospitals (33). Both have
427 components targeted at individuals (e.g., online tool/website, patient leaflets) and at teams –
428 ‘implementation teams’ in ARK and practice teams in our intervention (e.g., implementation

429 guidance/website, champions). Implementation requires both individual and organisational change,
430 so the targets for, and processes in, implementation interventions are more complex and multi-level
431 than interventions focussed on individuals only. Other studies also evaluated the implementation of
432 intervention components similar to our implementation intervention (e.g., online training,
433 champions, outreach visits, leaflets) (43–45). However, unlike in these studies, we distinguished AMS
434 strategies (e.g., POC-CRPT, DPs) that aim to influence antibiotic prescribing decisions from
435 implementation strategies (e.g., champions, website) that aim to influence the uptake and
436 implementation of the AMS strategies in practices. This is illustrated by our two logic models where
437 we specified the intended ‘mechanisms of action’ of different types of intervention components.

438 Digital components (websites, e-learning modules) are important in our and many other
439 interventions, and are commonly used to provide training and education for clinicians. A systematic
440 review of eight trials in primary care found that digital education on antibiotic management was
441 more effective in improving knowledge and likely more cost-effective than traditional education
442 (46). Online AMS training for all patient-facing staff was also one of the highest-ranked AMS
443 interventions by primary care stakeholders in previous research (47).
444 Nevertheless, engagement with digital interventions remains challenging. Health professionals in the
445 ARK study were sceptical about digital education due to high workloads and limited time (the 30-
446 minute ARK e-module was shortened to 10 minutes)(33). Similarly, we found a main barrier to
447 optimising antibiotics and engaging with AMS strategies in general practice was limited time. Thus,
448 we revised the website, handouts and practice meeting slides until they were as concise as possible,
449 but how acceptable the time required to engage with them is remains uncertain. We also decided
450 not to offer the 10-minute POC-CRPT as it was deemed too time-consuming by clinicians. In our
451 focus groups (26), we found that an important barrier to using POC-CRPT and DPs was ambiguity
452 about evidence and when, and how, to use the strategies; and professionals in our workshops and
453 think-aloud interviews asked for evidence and clear guidelines on using these strategies.
454 Consequently, we needed to strike a balance between making the intervention short and not losing

455 important content, and between providing evidence and guidance while allowing flexibility and
456 autonomy.

457 We have previously identified the importance of national and local champions as facilitators
458 to engagement and implementation in our qualitative research with CCG and general practice
459 professionals (7) and with primary care stakeholders (47). Growing literature on champions and
460 leaders in primary care supports their important role in facilitating implementation of AMS
461 strategies (43,48) and other initiatives (e.g., 49,50). However, a qualitative study with Norwegian
462 GPs showed a need for leadership training and tensions between GPs' clinical and leadership roles
463 (51). We initially explored involving CCG prescribing advisors as champions but professionals in our
464 workshops suggested practice-based champions more suited to help implement the strategies
465 within practice contexts and support colleagues. However, they also suggested providing incentives
466 (e.g. paying for their time), which was unfeasible in our study and complex in the real-world context.
467 Finally, as we previously found (7), in-person communication in practices was preferred (e.g.,
468 practice meetings), although challenging with time constraints. Wider, national implementation of
469 interventions often means that digital, remote delivery is more feasible without the in-person
470 components (helping to lower cost and time requirements). For example, the 'STAR' communication
471 training initially involved digital training and a practice-based seminar, but it is currently available
472 online only (18,19). The 'TARGET' ('Treat Antibiotics Responsibly, Guidance, Education, Tools')
473 training initially also had digital and in-person elements, and its national implementation involves
474 training trainers to continue delivering in-person training (52,53). Our intervention promotes
475 practice meetings led by practice-based professionals, making it potentially more flexible and
476 sustainable in real-world settings, enabling ownership of the initiatives and implementation, and
477 consistent practice between professionals.

478 A recent framework for planning, conducting and disseminating AMR intervention research
479 has called for research to be more responsive to stakeholder needs and for interventions to be
480 better designed, including consideration of behavioural determinants, theory and logic-models (54).
481 Different approaches and tools have been established and used to develop health-related behaviour

482 change interventions (55); e.g., Medical Research Council guidance (56), Intervention Mapping (57),
483 the Behaviour Change Wheel (58), and the Person-Based Approach (PBA) (28–30). These approaches
484 can be also used to develop interventions to support implementation. We drew on the PBA for its
485 suitability for designing interventions with digital components and focus on stakeholder engagement
486 and co-design with target users; thus, helping increase the likelihood of the intervention being
487 relevant, acceptable and feasible.

488 However, we found challenges with the PBA. For example, it encourages a digital delivery
489 early in the intervention development process, which may not always be the most optimal delivery
490 format. Moreover, in complex behaviours, such as implementation of (also complex) AMS strategies,
491 it is challenging to identify the most important influences on behaviour and determinants of change.
492 For example, we identified over 41 types of influences on antibiotic prescribing from qualitative
493 research. It was unclear which were most important, and what other unidentified influences (e.g.,
494 subconscious) may also be important. We tried to address influences that were commonly reported
495 and that resonated most with stakeholders and the study team. This resulted in trying to address
496 many influences but to different extents (e.g., some only by including brief information on the
497 website). Finally, it is unclear how the many approaches to behaviour change intervention
498 development (55) may be incorporated with the many implementation frameworks and models
499 which exist (59). In our research, we were aware of the concepts included in the implementation
500 frameworks but did not use them explicitly; an implementation framework will be used to guide the
501 evaluation in the implementation study.

502 **Strengths and limitations**

503 We followed a pre-defined, systematic process to developing the intervention, identifying
504 and addressing views and experiences of target users, while also incorporating evidence- and
505 theory-based elements. We engaged a relatively large and diverse number of relevant stakeholders.
506 We also engaged citizens (members of the public) to better understand and incorporate patient
507 perspectives. In the qualitative sub-studies we reached data saturation. A strength was also our

508 multidisciplinary team of experienced researchers and clinicians, who led and advised on the
509 intervention development. We followed guidance for reporting interventions (42) and intervention
510 development studies (60) (checklists are in Supplementary Files 4 and 5).

511 Limitations of the study, and thus potentially of the developed intervention, remain. We
512 acknowledge that there are other effective AMS strategies that could be considered for
513 implementation (e.g., clinical decision support tools) and that our focus on the three evidence-based
514 AMS strategies was to some extent influenced by the expertise and interests of the research team
515 and the scope of our study. The interviewees were involved in intervention development so there
516 was potential for socially desirable answers in the workshops and think-aloud interviews. However,
517 our data show that participants expressed critical comments. Professionals attending the workshops
518 were likely to be more interested in AMS and optimising antibiotics so their views and experiences
519 might have differed from professionals less engaged in AMS. However, we also incorporated findings
520 and suggestions from focus groups conducted in high-prescribing practices. Some professionals
521 involved had previous experience of implementing/using the AMS strategies and could share their
522 experiences, whereas others had not used some of the AMS strategies (e.g., POC-CRPT) which meant
523 that they approached the strategies with fresh eyes. We conducted think-aloud interviews only and
524 did not conduct interviews after giving people time to use the website/resources on their own (as
525 suggested by Bradbury et al. (61)); these will be part of the mixed-methods evaluation in the next
526 stage. Not all suggestions were feasible or practical to address and there are wider contextual
527 influences that affect high antibiotic prescribing (62), which are beyond the target for one practice-
528 based intervention. In our qualitative data collection we relied on participants' reports of views and
529 experiences. These may differ from actual behaviour and do not uncover subconscious influences.
530 Thus, other methods, such as observations, may be also needed (e.g., in future studies). Finally, it is
531 as yet unclear how applicable and fitting the intervention has been during, and will be after, the
532 COVID-19 pandemic which has, at least temporarily, transformed how general practices work.

533 [Conclusions](#)

534 In this article we report the development of an implementation intervention which followed
535 a systematic, user- and stakeholder-focused process. We describe the multicomponent ‘Antibiotic
536 Optimisation’ intervention that aims to promote the implementation of evidence-based AMS
537 strategies in general practices. Our intervention targets individual- and practice-level behaviour
538 change processes. In the next stage of our research the intervention has been piloted and evaluated
539 in an implementation study. With increasing numbers of AMS strategies and interventions and
540 growing trial-based evidence of effectiveness, it is now critical to work towards bridging the gap
541 between evidence and practice, and improve implementation of evidence-based strategies,
542 particularly in high-prescribing practices that need to further optimise antibiotic prescribing.

543

544 [List of abbreviations](#)

545 AMR – antimicrobial resistance; AMS – Antimicrobial Stewardship; CCG – Clinical Commissioning
546 Group; DPs – Delayed/back-up Prescriptions; GP – General Practitioner; PBA – Person-Based
547 Approach; POC-CRPT – Point-of-care C-Reactive Protein testing.

548

549 [Declarations](#)

550 [Ethics approval and consent to participate](#)

551 The University of Oxford research ethics committee (ref. R59812) and NHS Health Research
552 Authority (ref. 19/HRA/0434) approved the study. All participants provided written or verbal
553 informed consent for participation in the study.

554 [Consent for publication](#)

555 Not applicable.

556 [Availability of data and materials](#)

557 The datasets analysed during this study are available from the corresponding author on reasonable
558 request.

559 [Competing interests](#)

560 The authors declare that they have no competing interests.

561 [Funding](#)

562 The study was funded by the Economic and Social Research Council (ESRC) through the Antimicrobial
563 Resistance Cross Council Initiative supported by the seven research councils in partnership with
564 other funders (grant reference: ES/P008232/1) and supported by the National Institute for Health
565 Research (NIHR) Health Protection Research Unit (HPRU) in Healthcare Associated Infections and
566 Antimicrobial Resistance at the University of Oxford and Imperial College London in partnership with
567 Public Health England, the NIHR Oxford Biomedical Research Centre, and the NIHR Imperial Patient
568 Safety Translational Research Centre (PSTRC-2016-004). ASW, AH and CCB are NIHR Senior
569 Investigators. This study was additionally supported by a small grant from the NIHR Imperial
570 Biomedical Research Centre managed by the Patient Experience Research Centre. The support of the
571 funders is gratefully acknowledged.

572

573 The funding bodies played no role in the design of the study and collection, analysis, and
574 interpretation of data, and in writing the manuscript. The views expressed are those of the authors
575 and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care or Public
576 Health England.

577 Manufacturers of point-of-care CRP tests had no financial relationship with this study or research
578 team, and no influence on the study design, conduct or interpretation of results.

579 [Authors' contributions](#)

580 AJB – contributed to study design and all stages of the intervention development; facilitated
581 participant recruitment, data collection and analysed the data; drafted the manuscript.

582 AC - contributed to study design and all stages of the intervention development; facilitated
583 participant recruitment, data collection and analysed the data; revised the manuscript.
584 ED – contributed to data collection and analysis.
585 CCB, MM, AH, ASW - obtained funding; contributed to study design and intervention development;
586 provided comments on the manuscript.
587 MMc – obtained funding; contributed to study design and all stages of the intervention
588 development; facilitated participant recruitment, data collection and analysed the data; revised the
589 manuscript.
590 STC - obtained funding; contributed to study design and all stages of the intervention development;
591 facilitated participant recruitment, data collection and analysed the data; revised the manuscript.
592 All authors read and approved the final manuscript.

593 [Acknowledgements](#)

594 We thank the health professionals and citizens for participating in the study.

595 This paper is part of the work of the STEP-UP study team ([https://www.expmedndm.ox.ac.uk/step-](https://www.expmedndm.ox.ac.uk/step-up/step-up)
596 [up/step-up](https://www.expmedndm.ox.ac.uk/step-up/step-up)) comprising: Philip E. Anyanwu, Aleksandra J. Borek, Nicole Bright, James Buchanan,
597 Christopher C. Butler, Anne Campbell, Ceire Costelloe, Benedict Hayhoe, Alison Holmes, Susan
598 Hopkins, Azeem Majeed, Monsey Mcleod, Michael Moore, Liz Morrell, Koen B. Pouwels, Julie V.
599 Robotham, Laurence S. J. Roope, Sarah Tonkin-Crine, Ann Sarah Walker, Sarah Wordsworth, Carla
600 Wright, Sara Yadav, Anna Zalevski.

601 **References**

- 602 1. Public Health England. English surveillance programme for antimicrobial utilisation and
603 resistance (ESPAUR) Report 2018 - 2019. London: Public Health England; 2019.
604 [https://webarchive.nationalarchives.gov.uk/20200806045257/https://www.gov.uk/governme](https://webarchive.nationalarchives.gov.uk/20200806045257/https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report)
605 [nt/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-](https://webarchive.nationalarchives.gov.uk/20200806045257/https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report)
606 [espaur-report](https://webarchive.nationalarchives.gov.uk/20200806045257/https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report). Accessed 5 May 2021.
- 607 2. Tonkin-Crine SK, Tan PS, van Hecke O, Wang K, Roberts NW, McCullough A, et al. Clinician-
608 targeted interventions to influence antibiotic prescribing behaviour for acute respiratory
609 infections in primary care: an overview of systematic reviews. *Cochrane Database Syst Rev*.
610 2017 07;9:CD012252.
- 611 3. McDonagh MS, Peterson K, Winthrop K, Cantor A, Lazur BH, Buckley DI. Interventions to
612 reduce inappropriate prescribing of antibiotics for acute respiratory tract infections: summary
613 and update of a systematic review. *J Int Med Res*. 2018;46(8):3337–57.
- 614 4. Köchling A, Löffler C, Reinsch S, Hornung A, Böhmer F, Altiner A, et al. Reduction of antibiotic
615 prescriptions for acute respiratory tract infections in primary care: a systematic review.
616 *Implement Sci*. 2018;13(1):47.
- 617 5. NHS England. Quality Premium. <https://www.england.nhs.uk/ccg-out-tool/qual-prem>.
618 Accessed 5 May 2021.
- 619 6. PrescQIPP. <https://www.prescqipp.info>. Accessed 5 May 2021.
- 620 7. Borek AJ, Anthierens S, Allison R, McNulty CAM, Lecky DM, Costelloe C, et al. How did a Quality
621 Premium financial incentive influence antibiotic prescribing in primary care? Views of Clinical
622 Commissioning Group and general practice professionals. *J Antimicrob Chemother*.
623 2020;75(9):2681–8.
- 624 8. Allison R, Lecky DM, Beech E, Costelloe C, Ashiru-Oredope D, Owens R, et al. What
625 antimicrobial stewardship strategies do NHS commissioning organizations implement in
626 primary care in England? *JAC Antimicrob Resist*. 2020;2(2).
- 627 9. Spurling GK, Mar CBD, Dooley L, Foxlee R, Farley R. Delayed antibiotic prescriptions for
628 respiratory infections. *Cochrane Database of Systematic Reviews*. 2017;9.
- 629 10. Little P, Stuart B, Francis N, Douglas E, Tonkin-Crine S, Anthierens S, et al. Effects of internet-
630 based training on antibiotic prescribing rates for acute respiratory-tract infections: a
631 multinational, cluster, randomised, factorial, controlled trial. *The Lancet*.
632 2013;382(9899):1175–82.
- 633 11. Little P, Stuart B, Francis N, Douglas E, Tonkin-Crine S, Anthierens S, et al. Antibiotic prescribing
634 for acute respiratory tract infections 12 months after communication and CRP training: A
635 randomized trial. *Ann Fam Med*. 2019;17(2):125–32.
- 636 12. Yardley L, Douglas E, Anthierens S, Tonkin-Crine S, O'Reilly G, Stuart B, et al. Evaluation of a
637 web-based intervention to reduce antibiotic prescribing for LRTI in six European countries:
638 quantitative process analysis of the GRACE/INTRO randomised controlled trial. *Implement Sci*.
639 2013;8:134.
- 640 13. Francis NA, Butler CC, Hood K, Simpson S, Wood F, Nuttall J. Effect of using an interactive
641 booklet about childhood respiratory tract infections in primary care consultations on

- 642 reconsulting and antibiotic prescribing: a cluster randomised controlled trial. *BMJ*.
643 2009;339:b2885.
- 644 14. Gulliford MC, Prevost AT, Charlton J, Juszczuk D, Soames J, McDermott L, et al. Effectiveness
645 and safety of electronically delivered prescribing feedback and decision support on antibiotic
646 use for respiratory illness in primary care: REDUCE cluster randomised trial. *BMJ*.
647 2019;364:l236.
- 648 15. Little P, Moore M, Kelly J, Williamson I, Leydon G, McDermott L, et al. Delayed antibiotic
649 prescribing strategies for respiratory tract infections in primary care: pragmatic, factorial,
650 randomised controlled trial. *BMJ*. 2014;348:g1606.
- 651 16. Little P, Stuart B, Hobbs FDR, Butler CC, Hay AD, Delaney B, et al. Antibiotic prescription
652 strategies for acute sore throat: a prospective observational cohort study. *Lancet Infect Dis*.
653 2014;14(3):213–9.
- 654 17. Little P, Stuart B, Smith S, Thompson MJ, Knox K, Bruel A van den, et al. Antibiotic prescription
655 strategies and adverse outcome for uncomplicated lower respiratory tract infections:
656 prospective cough complication cohort (3C) study. *BMJ*. 2017;357:j2148.
- 657 18. Butler CC, Simpson SA, Dunstan F, Rollnick S, Cohen D, Gillespie D, et al. Effectiveness of
658 multifaceted educational programme to reduce antibiotic dispensing in primary care: practice
659 based randomised controlled trial. *BMJ*. 2012;344:d8173.
- 660 19. STAR: Stemming the Tide of Antibiotic Resistance.
661 <https://www.healthcarepd.com/course/star-stemming-the-tide-of-antibiotic-resistance>.
662 Accessed 5 May 2021.
- 663 20. When should I worry? <http://www.whenshouldiworry.com>. Accessed 5 May 2021.
- 664 21. Johnson M, Cross L, Sandison N, Stevenson J, Monks T, Moore M. Funding and policy incentives
665 to encourage implementation of point-of-care C-reactive protein testing for lower respiratory
666 tract infection in NHS primary care: a mixed-methods evaluation. *BMJ Open*.
667 2018;8(10):e024558.
- 668 22. Eley CV, Sharma A, Lecky DM, Lee H, McNulty CAM. Qualitative study to explore the views of
669 general practice staff on the use of point-of-care C reactive protein testing for the
670 management of lower respiratory tract infections in routine general practice in England. *BMJ*
671 *Open*. 2018;8(10):e023925.
- 672 23. Huddy JR, Ni MZ, Barlow J, Majeed A, Hanna GB. Point-of-care C reactive protein for the
673 diagnosis of lower respiratory tract infection in NHS primary care: a qualitative study of
674 barriers and facilitators to adoption. *BMJ Open*. 2016;6(3):e009959.
- 675 24. Ryves R, Eyles C, Moore M, McDermott L, Little P, Leydon GM. Understanding the delayed
676 prescribing of antibiotics for respiratory tract infection in primary care: a qualitative analysis.
677 *BMJ Open*. 2016;6(11):e011882.
- 678 25. Peters S, Rowbotham S, Chisholm A, Wearden A, Moschogianis S, Cordingley L, et al. Managing
679 self-limiting respiratory tract infections: a qualitative study of the usefulness of the delayed
680 prescribing strategy. *Br J Gen Pract*. 2011;61(590):e579-589.

- 681 26. Borek AJ, Campbell A, Dent E, Butler CC, Holmes A, Moore M, et al. Implementing interventions
682 to reduce antibiotic use: a qualitative study in high-prescribing practices. *BMC Fam Pract.*
683 2021;22(1):25.
- 684 27. STEP-UP study: Improving the uptake and SusTainability of Effective interventions to promote
685 Prudent antibiotic Use in Primary care. <https://www.expmedndm.ox.ac.uk/step-up>. Accessed 5
686 May 2021.
- 687 28. Yardley L, Ainsworth B, Arden-Close E, Muller I. The person-based approach to enhancing the
688 acceptability and feasibility of interventions. *Pilot Feasibility Stud.* 2015;1(1):37.
- 689 29. Yardley L, Morrison L, Bradbury K, Muller I. The person-based approach to intervention
690 development: application to digital health-related behavior change interventions. *J Med*
691 *Internet Res.* 2015;17(1):e30.
- 692 30. Morrison L, Muller I, Yardley L, Bradbury K. The person-based approach to planning,
693 optimising, evaluating and implementing behavioural health interventions. *Eur Health Psychol.*
694 2018;20(3):464.
- 695 31. The Person-Based Approach. <https://www.personbasedapproach.org>. Accessed 5 May 2021.
- 696 32. Anthierens S, Tonkin-Crine S, Douglas E, Fernandez-Vandellos P, Krawczyk J, Llor C, et al.
697 General practitioners' views on the acceptability and applicability of a web-based intervention
698 to reduce antibiotic prescribing for acute cough in multiple European countries: a qualitative
699 study prior to a randomised trial. *BMC Fam Pract.* 2012;13:101.
- 700 33. Santillo M, Sivyer K, Krusche A, Mowbray F, Jones N, Peto TEA, et al. Intervention planning for
701 Antibiotic Review Kit (ARK): a digital and behavioural intervention to safely review and reduce
702 antibiotic prescriptions in acute and general medicine. *J Antimicrob Chemother.*
703 2019;74(11):3362–70.
- 704 34. Borek AJ, Wanat M, Atkins L, Sallis A, Ashiru-Oredope D, Beech E, et al. Optimising
705 antimicrobial stewardship interventions in English primary care: a behavioural analysis of
706 qualitative and intervention studies. *BMJ Open.* 2020;10(12):e039284.
- 707 35. Borek AJ, Wanat M, Roberts N, Atkins L, Sallis A, Tonkn-Crine S. Exploring the Implementation
708 of Interventions to Reduce Antibiotic Use (ENACT) Study: Report. London: Public Health
709 England; 2019.
- 710 36. Palin V, Mölter A, Belmonte M, Ashcroft DM, White A, Welfare W, et al. Antibiotic prescribing
711 for common infections in UK general practice: variability and drivers. *J Antimicrob Chemother.*
712 2019;74(8):2440–50.
- 713 37. Curtis HJ, Walker AJ, Mahtani KR, Goldacre B. Time trends and geographical variation in
714 prescribing of antibiotics in England 1998–2017. *J Antimicrob Chemother.* 2019;74(1):242–50.
- 715 38. Hope EC, Crump RE, Hollingsworth TD, Smieszek T, Robotham JV, Pouwels KB. Identifying
716 English practices that are high antibiotic prescribers accounting for comorbidities and other
717 legitimate medical reasons for variation. *EclinicalMedicine.* 2018;6:36–41.
- 718 39. Cane J, O'Connor D, Michie S. Validation of the theoretical domains framework for use in
719 behaviour change and implementation research. *Implement Sci.* 2012;7(1):37.

- 720 40. Bradbury K, Morton K, Band R, Woezik A van, Grist R, McManus RJ, et al. Using the Person-
721 Based Approach to optimise a digital intervention for the management of hypertension. PLOS
722 ONE. 2018;13(5):e0196868.
- 723 41. Michie S, Richardson M, Johnston M, Abraham C, Francis J, Hardeman W, et al. The behavior
724 change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an
725 international consensus for the reporting of behavior change interventions. *Ann Behav Med*.
726 2013;46(1):81–95.
- 727 42. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of
728 interventions: template for intervention description and replication (TIDieR) checklist and
729 guide. *BMJ*. 2014;348:g1687–g1687.
- 730 43. Jeffs L, Mclsaac W, Zahradnik M, Senthinathan A, Dresser L, McIntyre M, et al. Barriers and
731 facilitators to the uptake of an antimicrobial stewardship program in primary care: A
732 qualitative study. PLOS ONE. 2020;15(3):e0223822.
- 733 44. Poß-Doering R, Kuehn L, Kamradt M, Glassen K, Fleischhauer Th, Kaufmann-Kolle P, et al.
734 Converting habits of antibiotic use for respiratory tract infections in German primary care
735 (CHANGE-3) - process evaluation of a complex intervention. *BMC Fam Pract*. 2020;21(1):274.
- 736 45. Petruschke I, Salm F, Kaufmann M, Freytag A, Gensichen J, Behnke M, et al. Evaluation of a
737 multimodal intervention to promote rational antibiotic use in primary care. *Antimicrob Resist*
738 *Infect Control*. 2021;10(1):66.
- 739 46. Kyaw BM, Car LT, Galen LS van, Agtmael MA van, Costelloe CE, Ajuebor O, et al. Health
740 professions digital education on antibiotic management: systematic review and meta-analysis
741 by the digital health education collaboration. *J Med Internet Res*. 2019;21(9):e14984.
- 742 47. Borek AJ, Wanat M, Sallis A, Ashiru-Oredope D, Atkins L, Beech E, et al. How can national
743 antimicrobial stewardship interventions in primary care be improved? A stakeholder
744 consultation. *Antibiotics*. 2019;8(4):207.
- 745 48. Høye S, Brænd AM, Spehar I. Quality improvement and antimicrobial stewardship in general
746 practice – the role of the municipality chief medical officer. A qualitative study. *Scand J Prim*
747 *Health Care*. 2020;38(3):352.
- 748 49. Nieuwboer MS, van der Sande R, van der Marck MA, Olde Rikkert MGM, Perry M. Clinical
749 leadership and integrated primary care: A systematic literature review. *Eur J Gen Pract*.
750 2019;25(1):7–18.
- 751 50. Looman W, Struckmann V, Köppen J, Baltaxe E, Cypionka T, Huic M, et al. Drivers of successful
752 implementation of integrated care for multi-morbidity: mechanisms identified in 17 case
753 studies from 8 European countries. *Soc Sci Med*. 2021;113728.
- 754 51. Spehar I, Sjøvik H, Karevold KI, Rosvold EO, Frich JC. General practitioners' views on leadership
755 roles and challenges in primary health care: a qualitative study. *Scand J Prim Health Care*.
756 2017;35(1):105–10.
- 757 52. McNulty C, Hawking M, Lecky D, Jones L, Owens R, Charlett A, et al. Effects of primary care
758 antimicrobial stewardship outreach on antibiotic use by general practice staff: pragmatic
759 randomized controlled trial of the TARGET antibiotics workshop. *J Antimicrob Chemother*.
760 2018;73(5):1423–32.


- 761 53. TARGET Antibiotic Toolkit (Treat Antibiotics Responsibly, Guidance, Education, Tools).
762 <https://www.rcgp.org.uk/TARGETantibiotics>. Accessed 5 May 2021.
- 763 54. Rogers Van Katwyk S, Hoffman SJ, Mendelson M, Taljaard M, Grimshaw JM. Strengthening the
764 science of addressing antimicrobial resistance: a framework for planning, conducting and
765 disseminating antimicrobial resistance intervention research. *Health Res Pol Syst*.
766 2020;18(1):60.
- 767 55. O’Cathain A, Croot L, Sworn K, Duncan E, Rousseau N, Turner K, et al. Taxonomy of approaches
768 to developing interventions to improve health: a systematic methods overview. *Pilot Feasibility*
769 *Stud*. 2019;5(1):41.
- 770 56. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating
771 complex interventions: the new guidance. *BMJ*. 2008;337(sep29 1):a1655–a1655.
- 772 57. Bartholomew LK, Parcel GS, Kok G, Gottlieb NH, Fernandez ME. Planning health promotion
773 programs: an intervention mapping approach. 4th ed. San Francisco: Jossey-Bass; 2016.
- 774 58. Michie S, Atkins L, West R. *The Behaviour Change Wheel: A Guide To Designing Interventions*.
775 London: Silverback Publishing; 2014.
- 776 59. Lynch EA, Mudge A, Knowles S, Kitson AL, Hunter SC, Harvey G. “There is nothing so practical as
777 a good theory”: a pragmatic guide for selecting theoretical approaches for implementation
778 projects. *BMC Health Serv Res*. 2018;18(1):857.
- 779 60. Duncan E, O’Cathain A, Rousseau N, Croot L, Sworn K, Turner KM, et al. Guidance for reporting
780 intervention development studies in health research (GUIDED): an evidence-based consensus
781 study. *BMJ Open*. 2020;10(4):e033516.
- 782 61. Bradbury K, Watts S, Arden-Close E, Yardley L, Lewith G. Developing digital interventions: A
783 methodological guide. *Evid Based Complement Alternat Med*. 2014;2014:e561320.
- 784 62. Borek AJ, Anthierens S, Allison R, McNulty CAM, Anyanwu PE, Costelloe C, et al. Social and
785 contextual influences on antibiotic prescribing and antimicrobial stewardship: A qualitative
786 study with Clinical Commissioning Group and general practice professionals. *Antibiotics*.
787 2020;9(12):859.

788


789

790 Figures


791 Figure 1. Logic model 1 for the three AMS strategies



794 Figure 2. Logic model 2 for the implementation intervention



800 **Figure 3. Components of the Antibiotic Optimisation implementation intervention**



801

802

Accepted version

804 Table 1. Summary of the implementation intervention development process

Stages	Steps	Person-Based Approach (28–30)
Planning & design of the intervention	<ol style="list-style-type: none"> 1. Defining the problem in behavioural terms, identifying target behaviours, users and influences on behaviour (literature scoping; qualitative research; expert input) 2. Creating guiding principles & theoretical modelling (logic modelling) 	Intervention planning: <ul style="list-style-type: none"> • Literature scoping and review • Qualitative research with target users • Formulating guiding principles (intervention design objectives, and key features of intervention) • Behavioural analysis and construction of logic model
Developing the intervention (components)	<ol style="list-style-type: none"> 3. Developing (drafting) intervention components & materials (design workshops) 4. Refining intervention materials (think-aloud interviews) 	Intervention optimisation: <ul style="list-style-type: none"> • Draft/refine intervention materials • Qualitative piloting of draft materials • Refine guiding principles • Revisit behavioural analysis and refine logic model
Implementing and evaluating the intervention	<ol style="list-style-type: none"> 5. Implementing the intervention in real-life context 6. Mixed-methods evaluation 	Mixed-methods process evaluation: <ul style="list-style-type: none"> • Quantitative research • Qualitative research with users • Triangulation • Examine theory-based questions drawn from logic model

Table 2. Influences on antibiotic prescribing and optimisation

Types of influences	Influences on antibiotic prescribing & optimisation (identified and fully reported in (26,34,35))	Intervention components
Evidence & education	1. Clinician awareness of evidence & guidelines 2. Peer discussion & learning 3. Clinician training/education on antibiotic prescribing 4. Advice from & influence of relevant experts	Website Practice meetings, champion Website Website
Clinical experience & confidence	5. Clinical experience & confidence	Website, training
Clinical assessment	6. Clinical uncertainty about illness aetiology, severity and/or progression 7. Additional diagnostic information from testing	POC-CRPT POC-CRPT
Perceptions of patient's expectations & satisfaction	8. Perceptions of patient expectations of antibiotics 9. Preserving a good relationship with patient, patient satisfaction & avoiding conflict	3 AMS strategies 3 AMS strategies
Communication skills & strategies	10. Ability to elicit & manage patient's concerns & expectations 11. Ability to reassure & safety-net 12. Perceived importance of shared decision making 13. Ability & motivation to educate patients in consultations	Comms 3 AMS strategies Comms, DP Website
Time & workload	14. Time pressure & workload (e.g., wanting to save time & prevent future consultations) 15. Consultation length (& not wanting to lengthen consultations)	Website Website
Professional role & ethos	16. Perceptions of professional role & ethos	Website, champion
Awareness & perceptions of responsibility for AMS	17. Clinician awareness/knowledge of & attitude to AMS	Champion
Monitoring, feedback & accountability	18. Receiving feedback on prescribing	Practice meeting
Perceptions of own & others' prescribing	19. (In)Consistent approach to antibiotic prescribing between clinicians/organisations	Practice meeting, champion
Attitudes to & use of AMS strategies*	20. Views on & use of strategies 21. Access to resources to use strategies	3 AMS strategies 3 AMS strategies, resources
Additional influences identified in the focus groups in relation to POC-CRPT and DP (26)	22. Perceived fit of strategies with clinical roles and experience 23. Perceived usefulness of strategies as social tools to negotiate treatment and educate patients 24. Ambiguities about strategies (incl. evidence, when and how to use them, impact on antibiotic prescribing/use)	Website 3 AMS strategies Website, practice meeting

	25. Practice context (incl. ease of access, availability of dispensary, deprivation, patient characteristics, time pressures, costs, logistics / workflows)	Practice meeting, champions, resources
--	---	--

807 *Abbreviations used in the table: Comms – communication skills training (including interactive use of leaflets),*
808 *DP – delayed antibiotic prescriptions, POC-CRPT – point-of-care C-reactive protein testing.*

809 ** Strategies identified in the qualitative studies (in usual care, outside of trials) included only DPs and leaflets,*
810 *and not communication skills training or POC-CRPT; however, it can be assumed that similar influences are*
811 *relevant to all three AMS strategies.*

812

813 **Table 3. Guiding principles for the implementation intervention**

Design objectives	Key features of the implementation intervention
To support practice-wide implementation and use of the AMS strategies	<ul style="list-style-type: none"> • Promote use of the three evidence-based AMS strategies in general practices • Intervention features aimed at all practice professionals to support both individual and practice-level change • Support practices to develop and agree practice-wide, consistent approaches to using the AMS strategies • Nominate practice champions to provide peer encouragement and support
To support autonomy and enable tailoring in how the AMS strategies are used	<ul style="list-style-type: none"> • Offer a choice of leaflets and POC-CRPT equipment • Non-prescriptive on how practices should implement strategies • Non-prescriptive on how clinicians should use strategies (including clinical situations)
To persuade users that information and AMS strategies are evidence-based and trustworthy	<ul style="list-style-type: none"> • Clear references to evidence and guidelines • Endorsed by the President of the Royal College of General Practitioners • Videos and testimonials of practising clinicians explaining how they use the strategies • Description of intervention as developed by a multidisciplinary university-based team (including practising clinicians), with non-commercial research funding
To be brief and concise	<ul style="list-style-type: none"> • Website to take less than an hour to read • Text as concise as possible • Use of expandable boxes on the website with additional details • Handouts for clinicians with key messages maximum of one A4 page
To be easy to use and navigate	<ul style="list-style-type: none"> • Similar structure of webpages for each strategy • Access to all sections of the website from the navigation bar (no need to go through the website sequentially, but sequential use possible)

814

Table 4. Summary of feedback from the first set of design workshops and resulting changes

Main comments & suggestions	Main changes to the intervention
<p><i>Communication skills – Professional workshop:</i></p> <ul style="list-style-type: none"> • Already use communication skills but are open to new ideas for things to say to patients (especially those perceived as ‘difficult’ to communicate with about antibiotics); need to highlight what is new; suggestions to call it ‘enhancing your communication skills’, ‘finding the right words’ or ‘tips/ideas for things to say to patients’. • Provide example phrases but keep short to avoid lengthening the consultation. • Leaflets should be discussed with patients, not just handed-out. <p><i>Communication skills – Citizen workshop:</i></p> <ul style="list-style-type: none"> • Provide examples of helpful and unhelpful communication strategies (e.g., need for acknowledging illness, addressing pain, discussing side effects of antibiotics). • Leaflets can be helpful but should not replace the conversation. 	<ul style="list-style-type: none"> • Changed the communication webpage name & title of the handout for clinicians. • Highlighted that strategies may be particularly helpful with patients who are expecting antibiotics. • Example phrases provided on website. • More emphasis on side effects of antibiotics and using leaflets interactively.
<p><i>POC-CRPT – Professional workshop only:</i></p> <ul style="list-style-type: none"> • Need to be clear that tests shouldn’t be done in all patients; practices need an agreed protocol for when and how they will use the tests, and complete training in using and interpreting the tests. • Tests perceived as potentially helpful with ‘borderline’ patients and to benchmark clinicians’ ‘gut feeling’. 	<ul style="list-style-type: none"> • Additional training to be offered by a provider/trainer. • Suggestions of when tests can help included on webpage.
<p><i>Delayed prescriptions (DP) – Professional workshop:</i></p> <ul style="list-style-type: none"> • Calling them ‘back-up’ prescriptions preferred as more reassuring than ‘delayed’. • DP can be confusing to patients (‘why are you giving a prescription when explaining that antibiotics aren’t needed?’). • The 6R model for communicating about DP should be combined with the CHESTSSS communication steps; clinicians are unlikely to explicitly go through a list of 6Rs. Training should be simpler and shorter. • Post-dating prescriptions can be seen as patronising and lead to patient complaints. • Need for a consistent approach to DP across prescribers. <p><i>Delayed prescriptions (DP) – Citizen workshop:</i></p> <ul style="list-style-type: none"> • ‘Back-up’ preferred to ‘delayed’, or explanation that the prescription is ‘in case’. • DP perceived as confusing (‘why offer it after explaining that antibiotics won’t help?’); patients would prefer to re-consult rather than have a DP. • Need something to help patients remember how/when to use the DP. • Need clear communication on when antibiotics will work or not, and on when to use the DP (‘if you’re getting worse’ is too vague). 	<ul style="list-style-type: none"> • Used ‘back-up/delayed’ wording throughout website/resources. • Clarified the suggested use of DP with prognostic uncertainty rather than when patients don’t need antibiotics to avoid mixed messages; examples phrases provided to avoid confusion. • Removed 6Rs and replaced with acronym WAIT to refer to elements of communication about DP. • DP linked to communication strategies (CHESTSSS) on website. • Examples of helpful and unhelpful explanations of DP added to website.

<ul style="list-style-type: none"> • The 6R model perceived as long; suggestions to shorten it to a more meaningful acronym (e.g. WAIT). • Post-dating would be perceived as insulting as suggesting clinician's lack of trust in the patient. 	
<p><i>Champions – Professional workshop only:</i></p> <ul style="list-style-type: none"> • Champions for antibiotics/AMS are helpful, otherwise focus is lost among other priorities. The champion needs to be someone who is already part of practice team (e.g. not someone from CCG). • Need to involve the whole practice team and agree a consistent approach to antibiotics. • Practice antibiotic champions could lead practice meetings/training. 	<ul style="list-style-type: none"> • Focus on practice champions rather than CCG champions. • Practice meetings to involve discussions and promote consensus on practice-wide approaches.
<p><i>Other key comments about implementation intervention – Professional workshop only:</i></p> <ul style="list-style-type: none"> • Need to help clinicians see how the training will be useful for them and their practice. • Make the training a part of the existing electronic system/training programme. • Present information in varied ways to cater for different preferences and learning styles. • Keep the training/information as brief as possible; use bullet points rather than long sentences or paragraphs. • Have summary sheets (up to one side of A4) to briefly summarise/highlight key messages. 	<ul style="list-style-type: none"> • Refer to benefits of using the strategies promoted to optimise antibiotics on the website home page. • Made the text more concise; used more bullet points, boxes, and tables. • Provided two handouts for clinicians to summarise communication and DP.

Accepted version

Table 5. Main changes to the intervention following the second set of design workshops

Website section	Main changes made in result of the suggestions in the second workshop
Overall website	<ul style="list-style-type: none"> • Replaced references to 'GPs' with 'prescribers'. • Added a Resources webpage with a list of all downloadable leaflets and resources, links to additional external resources (e.g. TARGET toolkit) and research papers/evidence. • Reduced the number of separate webpages for each section and moved non-essential text into expandable boxes for use if people want more details.
Home webpage	<ul style="list-style-type: none"> • Main focus on the three AMS strategies, with short explanations what they are and direct links to these sections. • Presented the three AMS strategies in a purposeful order; communication skills and leaflets, POC-CRPT and DP.
Section on communication skills and leaflets	<ul style="list-style-type: none"> • Added videos with a GP giving examples of communication strategies (helpful phrases). • Clarified that despite focus on acute infections, these strategies can be applicable to other types of consultations. • Shortened the text; highlighted examples found particularly helpful and novel by workshops participants. • Added sections on 'benefits of leaflets' and 'how to use leaflets to engage patients'.
Section on POC-CRPT	<ul style="list-style-type: none"> • Addressed the concern that POC-CRPT may increase demand and appointments for tests. • Clarified when to use and not use POC-CRPT.
Section on DP	<ul style="list-style-type: none"> • Addressed the concern that patients use DPs immediately by referring to trial evidence that shows that most (2/3) patients don't end up using DP. • Clarified that DP should not be offered if the GP doesn't think antibiotics are clinically needed, but rather instead of immediate antibiotics. • Highlighted the potential benefits of DP (e.g., reducing re-consultations or 'doctor-shopping').
Section on Implementation Support and Champions	<ul style="list-style-type: none"> • Explained who is meant by a practice Antibiotic Champion. • Explained why champions are important. (Suggestion to offer financial incentives was unaddressed as unfeasible.) • Suggested that champions may identify another professional to help with some activities.

Table 6. Summary of feedback from think-aloud interviews and resulting changes

Website section	Example suggestions from think-aloud interviews with health professionals	How they were addressed
Home page	<ul style="list-style-type: none"> • The website was perceived as unattractive without pictures. • Unclear why these three AMS strategies are promoted. • Unclear logo. More 'branding' would seem helpful. 	<ul style="list-style-type: none"> ➤ Added pictures for each AMS strategy. ➤ Clarified reasons for promoting the three strategies. ➤ Unchanged as participants held different views and was not considered a priority.
Section on communication strategies	<ul style="list-style-type: none"> • Example phrases and mock conversations liked. • Perceived difficulty with using leaflets with patients where English isn't their first language; unclear how they could access leaflets in other languages from the website. • Some disliked the mnemonic CHESTSSS, seen as hard to remember. • Too many webpages to go through to access the leaflets. 	<ul style="list-style-type: none"> ➤ Added more example phrases. ➤ Highlighted availability of leaflets in other languages and provided a link to them. ➤ CHESTSSS retained as covering all key elements. ➤ Moved all information on leaflets to one webpage.
Section on POC-CRPT	<ul style="list-style-type: none"> • References to NICE guideline should be highlighted. • Would like more information on using and interpreting results for different conditions. • Add information about manufacturer's training and quality control tests. • Questioned if the website/project was funded by CRP test producers. • Would like a template or Standard Operating Procedures (SOP) for using POC-CRPT in practices. 	<ul style="list-style-type: none"> ➤ NICE guidelines and trial evidence highlighted. ➤ No evidence for different conditions (other than respiratory infections) so no change. ➤ Added details on training and quality control. ➤ Clarified sources of funding. ➤ No template/SOP provided; suggested questions to agree on practice approach in meeting slides.
Section on DP	<ul style="list-style-type: none"> • Concerned about 'red flags' and need for reconsultation or urgent care. • Highlight the information on typical duration of common infections. • Some confusion about the different names for DP used. 	<ul style="list-style-type: none"> ➤ Added information on red flags (e.g. sepsis). ➤ Added a specific table on typical duration of infections. ➤ 'Back-up/delayed' retained as different people prefer/use different names.
Section on Implementation Support and Champions	<ul style="list-style-type: none"> • More focus on addressing concerns and suggested actions for champions, rather than reasons for promoting AMS. • Practice meeting slides need to be shorter (for 5-10 min meetings). • Unclear who the resources for antibiotic champion webpage/link is for. • Information seemed targeted at those who already are champions and not encouraging people to become one. 	<ul style="list-style-type: none"> ➤ Shortened the text on reasons and benefits, and expanded actions for champions. ➤ Shortened slides and divided into multiple sets. ➤ Called the webpage 'implementation support'. ➤ Edited text to clarify the information is for everyone promoting prudent prescribing.

List of Supplementary Files

Supplementary File 1. Complete table of influences on antibiotic prescribing and optimisation

- Format: pdf. Description: Complete table of influences on antibiotic prescribing and optimisation, including influences not addressed in the implementation intervention.

Supplementary File 2. Theoretical Domains Framework constructs and Behaviour Change Techniques

- Format: pdf. Description: Influences on antibiotic prescribing matched with Theoretical Domains Framework constructs, intervention components and behaviour change techniques.

Supplementary File 3. Details of the Antibiotic Optimisation implementation intervention

- Format: pdf. Description: additional details of the components and content of the implementation intervention.

Supplementary File 4. The TIDieR checklist

- Format: pdf. Description: the completed Template for Intervention Description and Replication (TIDieR) checklist.

Supplementary File 5. The GUIDED checklist

- Format: pdf. Description: the completed Guidance for reporting intervention development studies in health research (GUIDED) checklist.